Evidence map›Paper›PMID 33233560›Full record

ReviewFoods (Basel, Switzerland)2020

Food Ingredients and Active Compounds against the Coronavirus Disease (COVID-19) Pandemic: A Comprehensive Review.

Charis M Galanakis, Turki M S Aldawoud, Myrto Rizou, Neil J Rowan, Salam A Ibrahim

Open access · goldAbstract readReview
In one paragraph

Review in Foods (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers.

0numbers the graph read from it
0cells of the map it votes in
75citing papers in PubMed
4.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

75 citing papers in PubMed, 235 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Innate Immune-Enhancing Effect ofJournal of microbiology and biotechnology · 2024
    Article
  6. Article
  7. Article
  8. The Future of Food.Foods (Basel, Switzerland) · 2024
    Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

15 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 3 countries.

Charis M GalanakisResearch & Innovation Department, Galanakis Laboratories, 73131 Chania, Greece.ORCID 0000-0001-5194-0818
Turki M S AldawoudCollege of Science, King Saud University, Riyadh 12372, Saudi Arabia.
Myrto RizouResearch & Innovation Department, Galanakis Laboratories, 73131 Chania, Greece.
Neil J RowanBioscience Research Institute, Athlone Institute of Technology, Dublin Road, N37 F6D7 Athlone, Ireland.ORCID 0000-0003-1228-3733
Salam A IbrahimFood and Nutritional Sciences Program, North Carolina Agricultural and Technical State University, Greensboro, NC 27401, USA.ORCID 0000-0001-5395-9993
King Saud University · SAAthlone Institute of Technology · IENorth Carolina Agricultural and Technical State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As media reports have noted, the COVID-19 pandemic has accelerated market mainstreaming of immune-boosting food bioactives, supplements, and nutraceuticals. However, most studies reporting on the potential of bioactives against COVID-19 transmission have been uploaded as preprints with little opportunity to revise content for benefit and impact. The current review discusses current best evidence and information underpinning the role of food ingredients and bioactive compounds in supporting immune functions in humans and animals, specifically in the prevention and treatment of COVID-19 disease. Up to now, some evidence from randomized population and clinical trials has suggested that vitamin D levels may be linked to COVID-19 transmission and severity. Numerous theoretical studies have pointed to polyphenols and particularly flavonoids as potential inhibitors of SARS-CoV-2 infection. There is also inconclusive evidence to support the future use of β-glucan to address COVID-19 due in part to variability in immune response arising from heterogeneity in polysaccharide branch and chain length for different sources and the absence of a standardized extraction method. To confirm the promising outcomes and hypotheses for bioactive compounds, more randomized and controlled clinical studies are needed. The results of such studies would have a profound effect on the prospects of food supplements and nutraceuticals as potential prophylaxis against COVID-19 and serve to help consumers to protect themselves during the post-lockdown recovery era.

Indexed as

COVID-19functional foodsimmune systemnutraceuticalsSARS-CoV-2vitamin D

Identifiers

PMID33233560
PMCPMC7699782
OpenAlexW3102953020

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.